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ABSTRACT
Background
Treatment recommendations for the same condition from different guideline bodies often
disagree, even when the same randomized controlled trial (RCT) evidence is cited. Guideline
appraisal tools focus on methodology and quality of reporting, but not on the nature of the
supporting evidence. This study was done to evaluate the quality of the evidence (based on
consideration of its internal validity, clinical relevance, and applicability) underlying therapy
recommendations in evidence-based clinical practice guidelines.
Methods and Findings
A cross-sectional analysis of cardiovascular risk management recommendations was
performed for three different conditions (diabetes mellitus, dyslipidemia, and hypertension)
from three pan-national guideline panels (from the United States, Canada, and Europe). Of the
338 treatment recommendations in these nine guidelines, 231 (68%) cited RCT evidence but
only 105 (45%) of these RCT-based recommendations were based on high-quality evidence.
RCT-based evidence was downgraded most often because of reservations about the
applicability of the RCT to the populations specified in the guideline recommendation (64/
126 cases, 51%) or because the RCT reported surrogate outcomes (59/126 cases, 47%).
Conclusions
The results of internally valid RCTs may not be applicable to the populations, interventions,
or outcomes specified in a guideline recommendation and therefore should not always be
assumed to provide high-quality evidence for therapy recommendations.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org August 2007 | Volume 4 | Issue 8 | e250 1325
PLoS MEDICINEIntroduction
There has been a rapid expansion in the number of clinical
practice guidelines over the past decade and, as a result,
clinicians are frequently faced with several guidelines for
treatment of the same condition. Unfortunately, recommen-
dations may differ between guidelines [1,2], leaving the
clinician with a decision to make about which guideline to
follow. While it is easy to say that one should follow only those
guidelines that are ‘‘evidence based,’’ very few guideline
developers declare their documents to be non–evidence
based, and there is ambiguity about what ‘‘evidence based’’
really means in the context of guidelines. The term may be
interpreted differently depending on who is referring to the
guideline—the developer, who creates the guidelines, or the
clinician, who uses them. To their developers, ‘‘evidence-
based guidelines’’ are deﬁned as those that incorporate a
systematic search for evidence, explicitly evaluate the quality
of that evidence, and then espouse recommendations based
on the best available evidence, even when that evidence is not
high quality [3]. However, to clinicians, ‘‘evidence based’’ is
frequently misinterpreted as meaning that the recommenda-
tions are based solely on high-quality evidence (i.e., random-
ized clinical trials [RCTs]) [4]. Previous studies of guidelines
have focused almost exclusively on the elements embodied in
the ﬁrst deﬁnition of an evidence-based guideline. For
example, guideline appraisal tools assess the methodology
used in developing the guideline and the clarity with which
recommendations and the type of underlying evidence are
communicated in that guideline [5,6].
However, few studies have addressed the issue raised in the
second interpretation of an evidence-based guideline—that
is, the quality of the evidence underpinning ‘‘evidence-based’’
guidelines. Given the widespread availability of electronic
databases to search the literature, one would expect that
evidence-based guidelines would usually cite the same
evidence. However, an analysis of 15 guidelines for type 2
diabetes mellitus revealed little overlap—only ten studies (less
than 1% of all citations) were cited in at least six of these
guidelines, and the most frequently cited study in these
guidelines (the Diabetes Complication Control Trial, refer-
enced in 11 of 15 guidelines) was conducted exclusively in
patients without type 2 diabetes mellitus [7].
How then should the quality of evidence underlying
recommendations be evaluated? In those guidelines that use
explicit scales, virtually all are based solely on considerations
of study design and internal validity [8]. For example, RCTs
are graded higher than observational studies irrespective of
sample size, study conduct, endpoints evaluated, or the
applicability (i.e., generalizability) of the RCT to the pop-
ulations, interventions, and outcomes speciﬁed in the guide-
line recommendation. In order to incorporate external
validity, applicability, and clinical relevance into evidence
appraisal, we used an evidence grading scheme that has been
used (and reﬁned) for almost a decade by the Canadian
Hypertension Education Program (CHEP) [9]. The CHEP
scheme evaluates three (type of study, internal validity, and
directness) of the four domains recommended by the Grading
of Recommendations Assessment, Development and Evalua-
tion [GRADE] working group (http://www.gradeworkinggroup.
org/, last accessed 29 January 2007)—consistency between
studies is not explicitly evaluated in the CHEP scheme (except
in the assessment of meta-analyses) and, instead, CHEP places
primacy on the study achieving the highest evidence grading
for a particular recommendation [3].
We designed this study to evaluate the quality of the
evidence cited for cardiovascular risk management recom-
mendations in evidence-based clinical practice guidelines.
Methods
Selection of Guidelines
Based on the prevalence of these conditions in the
outpatient primary care setting and our collective areas of
clinical expertise, we restricted ourselves to national guide-
lines for the management of diabetes mellitus, dyslipidemia,
and hypertension. We a priori chose the most recent
guidelines from the United States, Canada, and Europe for
each disorder, as these are the national-level guidelines
Canadian clinicians are most commonly exposed to [10–19].
We deﬁned recommendations as any statements that advo-
cated a speciﬁc intervention for application in clinical care.
We focused on evaluating the evidence base for cardiovas-
cular risk management interventions in these guidelines, and
did not examine the evidence base underlying recommenda-
tions on diagnosis, monitoring, or prevention. Moreover, as
our interest was on the chronic treatment of these conditions,
we a priori excluded recommendations for pregnant,
hospitalized, or peri-operative individuals.
Quality Appraisal of the Guidelines
We appraised the quality of each guideline using the
standardized Appraisal of Guidelines Research and Evalua-
tion (AGREE) instrument (http://www.agreetrust.org/, last
accessed 29 January 2007), which consists of 23 items that
rate the various dimensions of quality for the overall
guideline using four-point Likert scales. The AGREE instru-
ment is organized into six independent domains, and the
score for each domain is calculated as a percentage of the
maximum possible score for that domain [20]. Three
investigators independently completed the AGREE instru-
ment for each guideline, and discrepancies were resolved by
consensus.
It should be noted that the AGREE appraisal is based on
consideration of the whole guideline (i.e., not for speciﬁc
recommendations within each guideline) and includes any
recommendations on diagnosis, monitoring, or prevention.
In contrast, our detailed analysis of the evidence underlying
recommendations focused solely on therapy recommenda-
tions.
Extraction of Recommendations and Underlying Evidence
After completing a training set to calibrate evidence
ratings, two investigators with expertise in both critical
appraisal and the topic areas of the chosen guidelines
reviewed each guideline, independently extracted recom-
mendations and the references cited by each guideline in
support of each cardiovascular therapy recommendation, and
graded the quality of the evidence as described in detail
below. We did not conduct literature searches and used only
the studies cited directly in the references list of each
guideline to evaluate the evidence base for that recommen-
dation. All evidence ratings for each cardiovascular therapy
recommendation were independently checked by a third
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Guidelines and Evidencereviewer (FAM), and any discrepancies were resolved by
consensus.
Grading Quality of the Underlying Evidence
We appraised the quality of evidence cited to support each
cardiovascular risk management recommendation using the
CHEP evidence-grading scheme (Figure 1). The CHEP
grading scheme was developed in 1999, has been used and
reﬁned in the seven annual updates of the Canadian hyper-
tension guidelines since then, and explicitly operationalizes
many elements of the GRADE scheme using a priori stand-
ardized rules of evidence (based on reference [21]) in a
fashion that has been shown to be reproducible within and
between reviewers trained in critical appraisal [9]. As we were
interested in exploring how many cardiovascular therapy
recommendations considered to be high quality in current
guidelines would have their evidence grading reduced when
factors beyond study design were taken into account, we
focused speciﬁcally on those recommendations citing RCTs
or systematic reviews of RCTs. In situations where several
RCTs or systematic reviews were cited in support of a
particular recommendation, we based our evidence grade on
the RCT or systematic review achieving the highest ranking
for that recommendation.
Pooled across all nine guidelines, inter-rater agreement on
whether a recommendation was based on RCT evidence or
not was 91% (kappa 0.80) and inter-rater agreement on
whether RCT evidence was high quality or not (grade A versus
B, C, or D on the CHEP scheme) was 89% (kappa 0.78).
Results
Characteristics of the Guidelines and Recommendations
The nine guidelines in our study (Table 1) [10–19] ranged
in size from ten pages to 284 pages and cited between 44 and
1,121 references. They provided a total of 1,005 recommen-
dations for diagnosis and prevention (n¼362) or treatment (n
¼ 643) for patients with diabetes mellitus, dyslipidemia, or
hypertension; 369 of the treatment recommendations in
these guidelines advocated cardiovascular risk management
therapies. Although only four of the guidelines [10,11,14,17]
provided grades for their underlying evidence, seven guide-
Figure 1. The Evidence-Grading Scheme Employed in this Study
Adapted from CHEP [9].
An ‘‘adequate’’ RCT is one with allocation concealment, blinded assessment of outcomes (if subjective), intention-to-treat analysis, adequate follow-up
(i.e., at least 90%, or losses to follow-up are too few to materially affect the results), and sufficient sample size to detect a clinically important difference
with power . 80% (1). Subgroup analysis was a priori, done within an adequate RCT, one of only a few tested, and there was sufficient sample size
within the examined subgroup to detect a clinically important difference with power . 80% (2). A sytematic review (SR) with direct comparisons is one
in which the comparison arms are derived from head-to-head comparisons within the same RCT (3). A systematic review with indirect comparisons is
one in which the comparison arms are derived from different RCTs, then extrapolations are made across RCTs (4). Adequate power in a negative study
implies that the 95% confidence interval excludes a clinically important difference (5). Effect estimates in each study included in the systematic review
are qualitatively similar (i.e., in the same direction) (6). Clinically important outcomes are ‘‘hard’’ endpoints such as death, stroke, or myocardial infarction
(7). End points have been consistently shown to be associated with the clinical end point in multiple studies (observational or RCT), and RCTs have
consistently demonstrated that improvement in the surrogate translates into a consistent and predictable improvement in the clinical end point (8).
doi:10.1371/journal.pmed.0040250.g001
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Guidelines and Evidencelines explicitly linked recommendations to evidence (either
within the text of the recommendation itself or at the end of
relevant sections of the guideline text); these 338 recom-
mendations formed the sample for this study.
Quality of the Guidelines
The standardized scores for each domain of the AGREE
instrument (averaged across guidelines within the same topic
areas) are outlined in Figure 2. While these guidelines were
scored highly for the clarity of their presentations and their
descriptions of ‘‘scope and purpose’’ and were judged to have
reasonable levels of editorial independence, they scored
poorly on the ‘‘stakeholder involvement’’ (due particularly
to lack of involvement of patient groups and prepiloting of
the guidelines) and ‘‘applicability’’ domains of the AGREE
instrument. Within the applicability domain, these guidelines
infrequently discussed resource implications, audit criteria,
or potential organizational changes necessary to implement
recommended therapies.
Quality of the Underlying Evidence
Of the 338 recommendations that endorsed particular
cardiovascular risk management therapies and cited evi-
dence, 231 (68%) cited an RCT or systematic review of RCTs
in support of that recommendation (Table 1). Of these 231
RCT-based recommendations, 105 (45%) received a grade A
using the CHEP grading scheme (corresponding to ‘‘high-
quality evidence’’ in the GRADE scheme), with the propor-
tion ranging between 37% and 51% in different guidelines
(Figure 3). Thus, only 28% (range 21% to 41% between
guidelines) of the 369 cardiovascular risk management
recommendations in these nine prominent national evi-
dence-based guidelines were directly supported by high-
quality evidence (Table 1).
The most frequent reason for downgrading RCT-based
therapy recommendations (64 [51%] of the 126 cases) were
concerns about the need to extrapolate from a highly selected
RCT population to the scenario and/or the target population
speciﬁed in the guideline. As an illustration, consider the
differences in quality of evidence underlying two antihyper-
tensive recommendations that were both based on RCT
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Figure 2. Summary of AGREE Domain Scores for Guidelines, Averaged
over Each Condition
doi:10.1371/journal.pmed.0040250.g002
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Guidelines and Evidenceevidence. The ﬁrst recommendation was for the use of
thiazides in individuals with hypertension. It cited a meta-
analysis [22] of 30 RCTs that proved conclusively the efﬁcacy
of thiazides in reducing cardiovascular events and mortality in
over 70,000 individuals with hypertension—this recommen-
dation was judged to be supported by high-quality (grade A)
evidence. In contrast, the second recommendation was for the
use of spironolactone for individuals with hypertension and
cited an RCT [23] of 1,663 patients with advanced heart failure
in which baseline blood pressures were normotensive (mean
122/75 mm Hg), and results for the hypertensive subgroup
were not reported separately. Although this spironolactone
recommendation was based on RCT evidence, its relevance
and applicability to the general hypertensive population is
sufﬁciently uncertain that we classiﬁed it as grade B (moderate
quality) evidence at best. As an aside, it should be noted that
RCT evidence was not downgraded if the RCT was conducted
primarily in men but the recommendation referred to people
in general, or if the RCT was conducted in a country other
than that from which the guideline arose. The second most
common reason for downgrading RCT-based recommenda-
tions (59 cases, 47%) were concerns about the clinical
relevance of the RCT—for example, the RCT reported the
effect of the recommended therapy on surrogate outcomes
only (e.g., levels of glucose, low-density lipoprotein cholester-
ol, or blood pressure) rather than patient-centered outcomes
such as death, myocardial infarction, or stroke. Illustrative
examples of RCT-based recommendations that were down-
graded are provided in Table 2.
The quality of the evidence base cited for cardiovascular
risk management therapies was not related to guideline
length (Pearson correlation coefﬁcient [r] ¼ 0.13, p ¼ 0.78),
number of references (r ¼ 0.20, p ¼ 0.67), or score on the
‘‘rigor of development’’ domain of the AGREE instrument (r
¼  0.03, p ¼ 0.96).
Discussion
In summary, we found that while two-thirds of cardiovas-
cular risk management therapy recommendations made in
the nine different guidelines we examined were based on
RCT evidence, less than half of these RCT-based recommen-
dations were deemed ‘‘high quality’’ using an evidence-
grading scheme that went beyond considerations of internal
validity alone to take into account clinical relevance and
direct applicability of the RCT to that recommendation. As a
result, less than one-third of recommendations that advo-
cated speciﬁc cardiovascular risk management therapies in
these evidence-based guidelines were actually based on high-
quality evidence.
The most frequent reason for RCT-based recommenda-
tions to be down-graded was that the RCT was conducted to
answer a particular question in a restricted study population
but was then extrapolated in the guideline to justify using the
tested intervention in a related, but different, clinical
scenario and/or in a more general population. In a similar
vein, other investigators have recently questioned whether
the evidence cited in the Third Report of the National
Cholesterol Education Program, or NCEP III, as support for
recommendations to use statins for primary prevention of
cardiovascular disease is directly applicable, since one-tenth
of the patients in the 16 ‘‘primary prevention’’ trials cited in
that guideline had cerebrovascular or peripheral vascular
disease at baseline [24].
As a corollary, it is evident that while a particular RCT may
be used as the basis for multiple recommendations, RCTs will
not provide the same quality of evidence for each recom-
mendation (and in some cases guideline developers may
extrapolate beyond the limits of the evidence in making
particular recommendations). For example, the 2003 Kidney
Disease Outcome Quality Initiative guidelines [25] recom-
mended statins for all patients with chronic kidney disease
and LDL . 2.59 mmol/l, including those with end-stage renal
disease, on the basis of RCTs such as the Heart Protection
Study which were positive, but excluded patients with end-
stage renal disease [26]. However, a recently published RCT
conducted in 1255 hemodialysis patients with type 2 diabetes
mellitus found no reduction in the primary outcome of
cardiovascular events or death but instead an unexpected
increase in the risk of stroke with statin therapy [27].
We do not mean to imply that recommendations should
not be made in the absence of high quality evidence or that
RCT evidence should not be extrapolated beyond the limits
of trial eligibility criteria. Indeed, we recognize that trialists
design RCTs with relatively homogenous populations in
order to maximize internal validity (at the expense of
external validity), and there are published guides on how
and when to extrapolate RCT evidence to individual patient
situations [28]. However, we do believe that transparency
about any extrapolation of RCT evidence is critical, partic-
ularly in light of studies demonstrating that the composition
and interpersonal dynamics of a guideline panel inﬂuence the
extent to which their consensus recommendations diverge
from the available evidence base [29–31].
Our ﬁndings that only some guidelines linked their
recommendations to citations and that only some used
explicit grading systems to communicate the quality of the
evidence echo earlier reviews [7,32–34]. Similarly, our ﬁnding
that many treatment recommendations are not based on RCT
evidence has been reported before in other ﬁelds [35].
However, our unique ﬁnding is that even those recommen-
dations in evidence-based guidelines that cite internally valid
RCTs as support may not be underpinned by high-quality
Figure 3. Percentage of Recommendations Citing RCTs That Were Based
on High-Quality Evidence in Each Guideline
Legend and references: ADA, American Diabetes Association [11];
Canadian Lipids, the Canadian Working Group on Hypercholesterolemia
and Other Dyslipidemias [13]; CDA, Canadian Diabetes Association [10];
CHEP, the Canadian Hypertension Education Program [16,17]; ESH/ISH,
European Society of Hypertension/International Society of Hypertension
[19]; JNC 7, Joint National Committee seventh report [18]; NCEP III, Third
Report of the National Cholesterol Education Program [14].
doi:10.1371/journal.pmed.0040250.g003
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Guidelines and Evidenceevidence. We did not compare the countries of origin for
cited studies, because previous studies have already estab-
lished that local evidence tends to be over-represented in
guidelines [7,36,37]. While the guidelines we studied were
published at different times, the range was narrow (2003–
2006) and our study focused on the type of evidence cited by
each guideline rather than by the speciﬁc recommendations
made.
Despite a number of strengths, our study has some
limitations. First, we did not systematically search for differ-
ent guidelines, but instead examined only a small sample of
guidelines; future studies should expand our work to explore
the quality of evidence underlying guidelines in other topic
areas. For example, we believe a systematic examination of all
guidelines produced by a particular organization (or, alter-
natively, all published guidelines in a particular topic area)
would provide useful additional insights. To do so, we
advocate the use of explicit grading schemes such as those
of CHEP or GRADE (as in the recently reported framework
for World Health Organization Rapid Advice Guidelines
[38]). However, while we found a high degree of inter-rater
reliability for assessing whether RCT evidence was high
quality or not (kappa 0.78 after all investigators completed a
training set), future studies should also assess the inter-rater
reliability scores for the GRADE or CHEP schemes if used by
investigators less familiar with the schemes. Second, because
the guidelines were inconsistent in how they cited studies in
support of therapy recommendations (with some providing
the citation directly with the recommendation and others
providing numerous citations at the end of supporting text
associated with recommendations), there is a potential risk we
may have misattributed citations to particular recommenda-
tions. We attempted to minimize this risk by having two
investigators extract recommendations and citations inde-
pendently for each guideline and by always biasing in favor of
the guideline (i.e., if several citations were attached to a
Table 2. Examples of Guideline Recommendations That Cited an Internally Valid Randomized Trial Which Did Not Provide High-Quality
Evidence for That Recommendation
Reason for Downgrade Recommendation Evidence
Cited
CHEP
Grade
Rationale for Downgrade
RCT evidence was downgraded
because of concerns about
applicability of the RCT results
to the population specified in
the guideline recommendation
Aldosterone antagonists for the treatment
of patients with hypertension and
concomitant heart failure
RALES [23] B Recommendation required extrapolation from an RCT
of 1,663 patients with advanced heart failure in which
baseline blood pressures were normotensive (mean
122/75 mm Hg) and results for the hypertensive
subgroup were not reported separately
Fibrates for primary prevention in patients
with diabetes mellitus and low-density
lipoprotein cholesterol below target but
elevated fasting triglycerides
VA-HIT [40] B Recommendation required extrapolation from a
secondary prevention RCT in 2,531 men with
coronary heart disease (all 627 individuals with
diabetes mellitus in the trial had coronary heart
disease at baseline)
RCT evidence was downgraded
because of concerns about
clinical relevance (i.e., primary
outcome was a surrogate
outcome)
DASH diet for all hypertensive individuals Sacks, et al. [41] B Statistically significant results, but primary outcome
in this 412-patient RCT was change in blood
pressure (a validated surrogate outcome)
ACE inhibitor plus angiotensin receptor
blocker as dual therapy for patients with
hypertension and advanced renal disease
COOPERATE [42] D Statistically significant results, but primary outcome
in this 263 patient RCT was ‘‘doubling of serum
creatinine or development of end stage renal failure’’
(an unvalidated surrogate outcome)
RCT evidence was downgraded
because recommendation was
based on post hoc subgroup
results
Aspirin for primary prevention of
cardiovascular events in patients with
diabetes mellitus
Antithrombotic
Trialists
Collaboration [43]
B Although the pooled estimate for 144,051 patients in
195 RCTs demonstrated a statistically significant
22% reduction in vascular events, the data in the
5,116 patients with diabetes mellitus and no vascular
disease at baseline was inconclusive (OR 0.93, 95%
CI 0.80–1.08)
Angiotensin receptor blockers for the
treatment of patients with isolated systolic
hypertension
LIFE secondary
publication [44]
B Randomization was not stratified within the subgroup
of 1,326 patients with isolated systolic hypertension;
all patients in this trial also had left ventricular
hypertrophy on ECG; losartan reduced the composite
cardiovascular endpoint compared to atenolol, but
difference was statistically significant only in adjusted
analysis
RCT evidence was downgraded
because the RCT had inadequate
power to rule out a clinically
important difference in a
negative study
Beta-blockers for the treatment of
hypertension in patients with diabetes
mellitus unable to tolerate ACE inhibitor
or angiotensin receptor blocker
UKPDS-39 [45] B Although there was no statistically significant
difference for the primary outcome with atenolol
versus captropril in this 758-patient trial, this
comparison was underpowered (134 deaths [RR 1.27,
95% CI 0.82–1.97], 107 myocardial infarctions [RR
1.20, 95% CI 0.82–1.76], and 259 ‘‘any diabetes
related endpoints’’ [RR 1.10, 95% CI 0.86–1.41])
ACE, angiotensin converting enzyme; CI, confidence interval; DASH, Dietary Approaches to Stop Hypertension; ECG, electrocardiogram; OR, odds ratio; RR, relative risk.
doi:10.1371/journal.pmed.0040250.t002
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Guidelines and Evidencerecommendation, we assigned the highest evidence rating
achieved by any of the studies to that recommendation).
However, future researchers may want to consider prospec-
tively surveying guideline developers to determine exactly
which pieces of evidence are considered for each recom-
mendation; also, documentation of the debate around the
evidence for particular recommendations in different over-
lapping guidelines would provide potentially interesting
insights. Finally, although our choice to restrict our analysis
to cardiovascular therapy recommendations may be per-
ceived as a limitation, it in fact strengthens our conclusions
since therapy recommendations are those most likely to be
based on RCT evidence. Thus, our ﬁndings represent a ‘‘best-
case’’ scenario, insofar as very few preventive or diagnostic
guideline recommendations are based on RCT evidence.
In conclusion, our ﬁnding that less than one-third of
treatment recommendations (and less than half of those
citing RCTs in support of the advocated treatment) were
based on high-quality evidence in national evidence-based
guidelines for common conditions should sound a note of
caution to consumers of clinical practice guidelines who
assume that the sobriquet ‘‘evidence based’’ means that all
recommendations contained therein are derived from high-
quality evidence. In particular, we have documented that
even evidence arising from internally valid RCTs may not be
directly applicable to the populations, interventions, and
outcomes speciﬁed in a guideline recommendation. As a
recent editorial noted, ‘‘external validity is the neglected
dimension in evidence ranking’’ [39]. Indeed, in order to
make the evidence base underlying therapy recommenda-
tions more transparent in future guidelines, we advocate
wider adoption of evidence-rating schemes (such as the CHEP
system or the GRADE system) that go beyond just judging the
internal validity of supporting evidence but also incorporate
considerations of the clinical relevance and applicability of
that evidence to the clinical scenario the recommendation is
being made for. A clearer understanding of the strengths and
limitations of the underlying evidence base will then permit
clinicians to individualize the application of practice guide-
line recommendations to their patients.
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Editors’ Summary
Background. Until recently, doctors largely relied on their own
experience to choose the best treatment for their patients. Faced with
a patient with high blood pressure (hypertension), for example, the
doctor had to decide whether to recommend lifestyle changes or to
prescribe drugs to reduce the blood pressure. If he or she chose the
latter, he or she then had to decide which drug to prescribe, set a target
blood pressure, and decide how long to wait before changing the
prescription if this target was not reached. But, over the past decade,
numerous clinical practice guidelines have been produced by govern-
mental bodies and medical associations to help doctors make treatment
decisions like these. For each guideline, experts have searched the
medical literature for the current evidence about the diagnosis and
treatment of a disease, evaluated the quality of that evidence, and then
made recommendations based on the best evidence available.
Why Was This Study Done? The recommendations made in different
clinical practice guidelines vary, in part because they are based on
evidence of varying quality. To help clinicians decide which recommen-
dations to follow, some guidelines indicate the strength of their
recommendations by grading them, based on the methods used to
collect the underlying evidence. Thus, a randomized clinical trial (RCT)—
one in which patients are randomly allocated to different treatments
without the patient or clinician knowing the allocation—provides
higher-quality evidence than a nonrandomized trial. Similarly, internally
valid trials—in which the differences between patient groups are solely
due to their different treatments and not to other aspects of the trial—
provide high-quality evidence. However, grading schemes rarely consid-
er the size of studies and whether they have focused on clinical or so-
called ‘‘surrogate’’ measures. (For example, an RCT of a treatment to
reduce heart or circulation [‘‘cardiovascular’’] problems caused by high
blood pressure might have death rate as a clinical measure; a surrogate
endpoint would be blood pressure reduction.) Most guidelines also do
not consider how generalizable (applicable) the results of a trial are to
the populations, interventions, and outcomes specified in the guideline
recommendation. In this study, the researchers have investigated the
quality of the evidence underlying recommendations for cardiovascular
risk management in nine evidence-based clinical practice guides using
these additional criteria.
What Did the Researchers Do and Find? The researchers extracted the
recommendations for managing cardiovascular risk from the current US,
Canadian, and European guidelines for the management of diabetes,
abnormal blood lipid levels (dyslipidemia), and hypertension. They
graded the quality of evidence for each recommendation using the
Canadian Hypertension Education Program (CHEP) grading scheme,
which considers the type of study, its internal validity, its clinical
relevance, and how generally applicable the evidence is considered to
be. Of 338 evidence-based recommendations, two-thirds were based on
evidence collected in internally valid RCTs, but only half of these RCT-
based recommendations were based on high-quality evidence. The
evidence underlying 64 of the guideline recommendations failed to
achieve a high CHEP grade because the RCT data were collected in a
population of people with different characteristics to those covered by
the guideline. For example, a recommendation to use spironolactone to
reduce blood pressure in people with hypertension was based on an RCT
in which the participants initially had congestive heart failure with
normal blood pressure. Another 59 recommendations were downgraded
because they were based on evidence from RCTs that had not focused
on clinical measures of effectiveness.
What Do These Findings Mean? These findings indicate that although
most of the recommendations for cardiovascular risk management
therapies in the selected guidelines were based on evidence collected in
internally valid RCTs, less than one-third were based on high-quality
evidence applicable to the populations, treatments, and outcomes
specified in guideline recommendations. A limitation of this study is that
it analyzed a subset of recommendations in only a few guidelines.
Nevertheless, the findings serve to warn clinicians that evidence-based
guidelines are not necessarily based on high-quality evidence. In
addition, they emphasize the need to make the evidence base
underlying guideline recommendations more transparent by using an
extended grading system like the CHEP scheme. If this were done, the
researchers suggest, it would help clinicians apply guideline recom-
mendations appropriately to their individual patients.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040250.
  Wikipedia contains pages on evidence-based medicine and on clinical
practice guidelines (note: Wikipedia is a free online encyclopedia that
anyone can edit; available in several languages)
  The National Guideline Clearinghouse provides information on US
national guidelines
  The Guidelines International Network promotes the systematic
development and application of clinical practice guidelines
  Information is available on the Canadian Hypertension Education
Program (CHEP) (in French and English)
  See information on the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) working group, an organization
that has developed an grading scheme similar to the CHEP scheme (in
English, Spanish, French, German, and Italian)
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